title: Oncologic results, functional outcomes, and complication rates of robotic-assisted radical prostatectomy: multicenter experience in Turkey including 1,499 patients.
abstract: BACKGROUND
  Robot-assisted radical prostatectomy (RARP) is a rising minimally invasive treatment of localized prostate cancer (PC). We present our multicenter experience of 1,499 consecutive cases with an analysis of complication rates, oncologic, and functional outcomes.
  
  
  METHODS
  From March 2005 through December 2012, details of 1,499 patients were retrospectively analyzed. Transperitoneal approach using a da-Vinci robotic system was used to perform RARP. Perioperative characteristics and postoperative oncologic and functional outcomes are reported.
  
  
  RESULTS
  The mean age was 61.3 years (37-77). Mean PSA level was 8.3 ng/ml. According to D'Amico classification, the percentage of patients with low-, intermediate-, and high-risk disease cases were 65.0, 30.1, and 4.8 %, respectively. Mean operative time was 181.9 min. Mean estimated blood loss was 225.4 cc (30-1,250). Positive surgical margin (PSM) was detected in 212 (14.1 %) patients. PSM rates in pT2, pT3, and pT4 stages were 6.1, 37.1, and 100 %, respectively. The overall complication rate due to modified Clavien classification was 6.1 %. Mean follow-up time was 26.7 months. Continence, potency, and biochemical recurrence rates were 88.7, 58.2, and 2.9 %, respectively.
  
  
  CONCLUSIONS
  Our analyses including high-volume centers, which is the first largest series in Turkey, show that RARP is a safe procedure, has low PSM rates, high continence, and potency rates for the treatment of localized PC at experienced centers.
authors.affiliation: Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.
authors.forename: A I
authors.initials: AI
authors.lastname: Tasci
authors.forename: I
authors.initials: I
authors.lastname: Tufek
authors.forename: E
authors.initials: E
authors.lastname: Gumus
authors.forename: A E
authors.initials: AE
authors.lastname: Canda
authors.forename: V
authors.initials: V
authors.lastname: Tugcu
authors.forename: F
authors.initials: F
authors.lastname: Atug
authors.forename: U
authors.initials: U
authors.lastname: Boylu
authors.forename: Z
authors.initials: Z
authors.lastname: Akbulut
authors.forename: S
authors.initials: S
authors.lastname: Sahin
authors.forename: A
authors.initials: A
authors.lastname: Simsek
authors.forename: A R
authors.initials: AR
authors.lastname: Kural
mesh_terms: D000328:Adult; D000368:Aged; D006801:Humans; D007610:Kallikreins / Q000097:blood; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000453:epidemiology*; D009367:Neoplasm Staging; D011183:Postoperative Complications / Q000453:epidemiology*; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology / Q000601:surgery*; D012189:Retrospective Studies; D065287:Robotic Surgical Procedures; D012735:Sexual Dysfunction, Physiological / Q000453:epidemiology*; D016896:Treatment Outcome; D014421:Turkey; D014549:Urinary Incontinence / Q000453:epidemiology*
chemical_list: C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen